| 查看: 554 | 回复: 1 | |||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | |||
[求助]
求翻译，站内信，大神求帮忙
|
|||
|
1. The incidences of invasive fungal infection are increasing due to number of immune compromised host and occurrence of antibiotic resistant strains [1]-[3]. The number of antifungal agent available for the treatment is limited and their use has been restricted because of toxicity or unfavorable pharmacokinetics profile. Hence, research interest has focused on discovery of safe and potent antifungal agent. One of the most successful approaches is to screen microbial resources to extract novel antifungal antibiotics. Drug discovery from natural products has been traditionally focused on empirical exploitation of the most prolific microbial groups: actinomycetes and filamentous fungi. The literature vividly displays that actinomycetes have been the origin of the largest number of new antibiotic drug candidates and also lead molecules with applications in many other therapeutic areas. Access to the microbial diversity of actinomycetes in the environment has traditionally been focused on intensive sampling from a wide diversity of geographical locations and habitats . One of the approaches is to explore untapped actinomycetes communities that might be associated with rhizospheres, plant endophytes, lichens, and entophytic bacteria [7] [8], as well as marine sediments and marine invertebrate-associated actinomycetes, which might facilitate isolation of novel microbial communities potentially producing novel chemical scaffolds . Oceans, making up 70.8% of the surface of planet earth, contain untapped actinobacterial resources of bioactive compounds. The salinity, low temperature, pressure and stress conditions in marine environments provoke a set of different metabolic pathways and defense system compared to their terrestrial counterparts, ensuring the potential ability to produce novel antibiotics [10]. According to recent findings, actinobacteria are widely distributed on the surface and inside animals and plants, in seawater and marine sediments. Marine-derived actinomycetes are rich sources of novel secondary metabolites having diverse bioactivity such as antimicrobial, antitumor and immunosuppressive. The novel structure, promising biological properties and prospects of fermentation-based mass production have led to the renewed interest in the search for potential drug from marine microorganism. During the ongoing screening program for the discovery of novel and superior antifungal compounds, an actinomycetes strain PM0525875 was isolated from a marine invertebrate. It showed potent in-vitro antifungal activity encompassing resistant fungal strains. The present work deals with the isolation and characterization of antifungal compound, Caerulomycin A from a marine-derived actinomycetes species. |
回复此楼» 猜你喜欢
请问哪里可以有青B申请的本子可以借鉴一下。
已经有4人回复
-
真诚求助：手里的省社科项目结项要求主持人一篇中文核心，有什么渠道能发核心吗
已经有6人回复
-
孩子确诊有中度注意力缺陷
已经有14人回复
-
三甲基碘化亚砜的氧化反应
已经有4人回复
-
请问下大家为什么这个铃木偶联几乎不反应呢
已经有5人回复
-
请问有评职称，把科研教学业绩算分排序的高校吗
已经有5人回复
-
2025冷门绝学什么时候出结果
已经有3人回复
-
天津工业大学郑柳春团队欢迎化学化工、高分子化学或有机合成方向的博士生和硕士生加入
已经有4人回复
-
康复大学泰山学者周祺惠团队招收博士研究生
已经有6人回复
-
AI论文写作工具：是科研加速器还是学术作弊器？
已经有3人回复
ssssllllnnnn 
至尊木虫 (知名作家)
Translator and Proofreader
- 翻译EPI: 1690
- 应助: 452 (硕士)
- 金币: 31580.9
- 红花: 100
- 帖子: 7681
- 在线: 19966.6小时
- 虫号: 3328089
- 注册: 2014-07-17
- 专业: 肿瘤发生
【答案】应助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ...
bxzc123: 金币+80, 翻译EPI+1, ★★★很有帮助 2014-11-02 13:28:12
bxzc123: 金币+80, 翻译EPI+1, ★★★很有帮助 2014-11-02 13:28:12
|
由于免疫缺陷宿主的数目和抗生素抗性菌株的出现，侵袭性真菌感染的发生率正在增加[1] - [3]。可用于治疗的抗真菌制剂的数量是有限的，而且，因为毒性或不利的药代动力学分布，它们的使用受到限制。因此，研究兴趣已集中在发现安全和有效的抗真菌剂。其中最成功的方法是筛选微生物资源已提取新型抗真菌抗生素。 从天然物品中发现药物历来是专注于最丰富的微生物群体——放线菌和丝状真菌的开发。文献中生动地表明，放线菌一直的数量最多的新抗生素药物候选物的来源，也是在许多其它治疗领域被应用最多的分子。获取放线菌在环境中的微生物多样性历来集中在从广泛多样的地理位置和栖息地密集采样。 一个办法是探索可能与根际，植物内生菌，地衣，和内生菌相关联，尚未开发的放线菌群落[7] [8]，以及海洋沉积物和海洋无脊椎动物相关的放线菌，这可能会促进分离新的微生物群落，产生新的化学支架。海洋占地球表面的70.8％，含有未开发的生物活性物质的放线菌资源。海洋环境具有的盐度，低温，压力和应力等条件可引发一组与地面条件下不同的代谢途径和防御体系，以确保生产新型抗生素的潜在能力[10]。根据最近的发现，放线菌广泛分布于动物和植物的体表和内部，在海水及海底沉积物中。来源于海洋的放线菌富含具有抗菌，抗肿瘤和免疫抑制等多样生物活性的新型次级代谢产物。结构新颖，有前途的生物特性和以发酵为基础的规模化生产已经引起了从海洋微生物寻找潜在药物的新兴趣。在正在进行的为发现新的优秀抗真菌化合物的筛选过程中，从海洋无脊椎动物分离到一种放线菌菌株PM0525875。该菌株在体外表现出强效的抗真菌活性，包括抗药菌株。目前的工作包括分离和鉴定一种抗真菌化合物，即来自于海洋放线菌属产生的青蓝霉素。 |
2楼2014-11-02 07:48:58